biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR
Vir Biotechnology
Vir Biotechnology clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1800 Owens St, Suite 900, San Francisco, California 94158, US
- Founded
- 2016
- Employees
- 479
- Programs
- 34
- Drugs
- 17
- Patents
- 6
Vir Biotechnology projects
10 ClinicalTrials.gov programs sponsored by Vir Biotechnology.
Vir Biotechnology has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Sotrovimab
Vir Biotechnology
COVID-19 Infection
1 trial -
VIR-1111
Vir Biotechnology
HIV I Infection
1 trial -
VIR-2218
Vir Biotechnology
Hepatic Impairment
1 trial -
VIR-2218
Vir Biotechnology
Renal Impairment
1 trial -
VIR-2482
Vir Biotechnology
Influenza A
1 trial -
VIR-3434
Vir Biotechnology
Chronic Hepatitis B
1 trial -
VIR-5500
Vir Biotechnology
Hormone-refractory Prostate Cancer
1 trial -
VIR-5525
Vir Biotechnology
Solid Tumor Malignancies
1 trial -
VIR-5818-V101
Vir Biotechnology
Participants with Locally Advanced or Metastatic HER2-Expressing Cancers
1 trial -
VRON-0200-AdC6
Vir Biotechnology
Chronic Hepatitis B
1 trial
Frequently asked questions
How many clinical projects does Vir Biotechnology have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.